The treatment approaches for lung cancer are rapidly evolving, and include integration of new systemic therapies (e.g. immunotherapy and targeted therapies) into combined modality approaches for non-metastatic disease and ablative radiation therapy approaches for oligo-metastatic disease. This session will review recent literature and guidelines for the treatment of lung cancer, and provide insights into tailoring of different combined modality therapy options for patients.
Participants will learn about the clinical outcomes and toxicity risks, and how to coordinate these new, complex multidisciplinary treatment approaches.
Furthermore, this session will review recent insights into toxicity risks for both conventional radiation therapy (especially in the postoperative setting and related to cardiac injury) and stereotactic body radiation therapy (especially for ultracentral tumors), and the implications of radiation therapy toxicity on newer combined modality approaches.
The activity is designed to meet the interests of radiation oncologists and radiation oncology residents.
Upon completion of this activity, participants should be able to do the following:
- Discuss the literature supporting novel combined modality therapy approaches that include immunotherapy, chemotherapy, surgery and/or radiation therapy in non-metastatic lung cancer.
- Discuss the pros and cons of different modalities of local therapy (surgery versus radiation) for each stage of lung cancer and appropriate situations to consider dual local therapy.
- Describe risk factors for severe radiation-related toxicity, including cardiac injury and central mediastinal structure injury for SBRT, and methods to mitigate these risks.
Raymond H. Mak, MD is employed by Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School. He has received honoraria from AstraZeneca, Novartis, Sio Capital Mgmt and Varian Medical Systems as well as grant/research funding from ViewRay. He had ownership equity in HealthAI.
All relevant financial relationships have been mitigated.
The person(s) above served as the developer(s) of this activity. Additionally, the Annual Refresher Course Planning Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.75 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.75 Certificate of AttendanceThis activity was designated for 1.75 AMA PRA Category 1 Credit™.